Palliative care ICD11 code: QC7A
Oral > Solid: 20 mg (as hydrochloride)
EML status history
Adolescents and adults
The recommendation is for this specific medicine
Patents have expired in most jurisdictions
Read more about patents.
Summary of evidence and Expert Committee recommendations
The Expert Committee recommended the deletion of fluoxetine for the treatment of depressive disorders in children from the complementary list of the EMLc. The Committee accepted that fluoxetine may be used in children younger than 12 years in some setting where there is limited access to mental health facilities and non-pharmacological interventions and may be recommended in some consensus guidelines. However, the Committee noted that the reported prevalence of depression in children younger than 12 years is low and considered that the current evidence for use of fluoxetine in this age group was inconclusive and insufficient to support its ongoing inclusion the EMLc. This recommendation therefore also applies to the listing of fluoxetine on the EMLc in Section 2.3 Medicines for other common symptoms in palliative care. The Committee noted that the prevalence of depression substantially increases throughout adolescence and into adulthood and confirmed that fluoxetine will remain included on the EML for the treatment of depression in adults.